<html><head> 
<title> T-Helper II Protocols </title>
</head>
<body>
<h1> T-HELPER II PROTOCOL LIST </h1><p>
This is a subset of the AIDS clinical trials supported by the T-Helper system. Because of confidentiality reason, only those protocols published by ACTG and CCTG are available here.
<OL>
<LI>

<a href="http://smi-web/projects/intermed-web/aidsprotocols/177Index.html"> <b>ACTG 177</b></a>:  Prohpylaxis Against Mycobacterium Tuberculosis (MTB) in Patients Who are Infected with the Human Immunodeficiency Virus (HIV) and
Suspected or Confirmed Latent MTB Infection  
<LI>


<a href="http://smi-web/projects/intermed-web/aidsprotocols/193aIndex.html"><b>ACTG193A</b> </A>:
A Randomized, Double-Blind, Four-Arm Study Comparing Combination Nucleoside,
Alternating Nucleoside, and Triple Convergent Therapy for the Treatment of
Advanced HIV Disease (CD4 ? 50/mm3) in Patients With a Prior History of
Nucleoside Monotherapy 
<LI>

<a href="http://smi-web/projects/intermed-web/aidsprotocols/244Index.html"> <b>ACTG 244</b> </a>:
A Double-blinded, Randomized Trial Comparing
Zidovudine (ZDV) vs ZDV + Didanosine (DDI) vs ZDV + DDI + Nevirapine in Asymptomatic Patients on ZDV Monotherapy Who Develop a Mutation at Codon 215 of HIV Reverse Transcriptase in Serum/Plasma
Viral RNA
<LI>

<a href="http://smi-web/projects/intermed-web/aidsprotocols/268Index.html"><b>ACTG 268  </b></a>:Gradual Initiation of Trimethoprim/Sulfamethoxazole as Primary Pneumocystis
Carinii Pneumonia Prophylaxis

<LI>

<a href="http://smi-web/projects/intermed-web/aidsprotocols/553Index.html"><b>CCTG 553 </b></a>:  The Treatment Of Extraneural Cryptococcosis With Fluconazole Plus Flucytosine In AIDS Patients

<LI>

<a href="http://smi-web/projects/intermed-web/aidsprotocols/549Index.html"><b>CCTG 549 </b> </a>: Evaluation of Clarithromycin And Clofazimine With And
Without Ethambutol In The Therapy Of Disseminated <i>Mycobacterium avium</i>
Complex Infection In Patients With AIDS

<LI>
CCTG 559 - HPMPC/CMV Viremia (CCTG559)</B>:
A Randomized Pilot Phase II Study of
1-(S)-(3-Hydroxy-2-Phosphonylmenthoxypropyl)-Cytosine Dihydrate (HPMPC) Versus
Deferred Treatment for Symptomatic, Persistent CMV Viremia in HIV-Infected
Patients Without End-Organ CMV Disease 

<p>

</body></html>